22 research outputs found
Breast and prostate cancer patients differ significantly in their serum Thymidine kinase 1 (TK1) specific activities compared with those hematological malignancies and blood donors: implications of using serum TK1 as a biomarker
Thymidine kinase 1 concentration in pleural effusion is a diagnostic marker and survival predictor for malignant pleural effusion
Examination of different pre-analytical conditions on the values of anti-mĂĽllerian hormone (AMH) measured using the Access AMH Assay
68Gallium-labelled prostate-specific membrane antigen ligand (68Ga-PSMA-11) promising radiotracer for PET/MRI or PET/CT of prostate cancer
Isocitrate Dehydrogenase-1 Mutations as Prognostic Biomarker in Glioblastoma Multiforme Patients in West Bohemia
Introduction. Glioblastoma multiforme (GBM) is the most malignant primary brain tumor in adults. Recent whole-genome studies revealed novel GBM prognostic biomarkers such as mutations in metabolic enzyme IDH—isocitrate dehydrogenases (IDH1 and IDH2). The distinctive mutation IDH1 R132H was uncovered to be a strong prognostic biomarker for glioma patients. We investigated the prognostic role of IDH1 R132H mutation in GBM patients in West Bohemia. Methods. The IDH1 R132H mutation was assessed by the RT-PCR in the tumor samples from 45 GBM patients treated in the Faculty Hospital in Pilsen and was correlated with the progression free and overall survival. Results. The IDH1 R132H mutation was identified in 20 from 44 GBM tumor samples (45.4%). The majority of mutated tumors were secondary GBMs (16 in 18, 89.9%). Low frequency of IDH1 mutations was observed in primary GBMs (4 in 26, 15.3%). Patients with IDH R132H mutation had longer PFS, 136 versus 51 days (P<0.021, Wilcoxon), and OS, 270 versus 130 days (P<0.024, Wilcoxon test). Summary. The prognostic value of IDH1 R132H mutation in GBM patients was verified. Patients with mutation had significantly longer PFS and OS than patients with wild-type IDH1 and suffered more likely from secondary GBMs
The evaluation of tumor markers and their impact on prognosis in gallbladder, bile duct, and cholangiocellular carcinomas – A pilot study
Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report.
Pancreatic ductal adenocarcinoma is one of the most difficult malignancies to
diagnose and treat. The aim of this article is to review how tumor markers can
aid the diagnosis and management of patients with this malignancy. The most
widely used and best validated marker for pancreatic cancer is CA 19-9.
Inadequate sensitivity and specificity limit the use of CA 19-9 in the early
diagnosis of pancreatic cancer. In non-jaundiced patients, however, CA 19-9 may
complement other diagnostic procedures. In patients with resectable pancreatic
cancer, presurgical and postresection CA 19-9 levels correlate with overall
survival. In advanced disease, elevated pretreatment levels of CA 19-9 are
associated with adverse patient outcome and thus may be combined with other
factors for risk stratification. Most, but not all, reports indicate that serial
levels of CA 19-9 correlate with response to systemic therapy. Use of CA 19-9
kinetics in conjunction with imaging is therefore recommended in monitoring
therapy. Although several potential serum and tissue markers for pancreatic
cancer are currently undergoing evaluation, none are sufficiently validated for
routine clinical use. CA 19-9 thus remains the serum pancreatic cancer marker
against which new markers for this malignancy should be judged